NorCom Information Technology AG

  • WKN: A12UP3
  • ISIN: DE000A12UP37
  • Land: Deutschland

Nachricht vom 17.07.2017 | 13:34

NorCom' DaSense supports Big Data project in China

DGAP-News: NorCom Information Technology AG / Key word(s): Contract

17.07.2017 / 13:34
The issuer is solely responsible for the content of this announcement.


NorCom Information Technology AG supplies its Big Data analysis software DaSense to the BMW Technology Office China. DaSense is to be used for a research project in Shanghai. The aim is to capture behavior of Chinese car drivers. The results are intended to provide information about the specific requirements of the target group on vehicles.

"Our solution DaSense is also suitable for individual projects with specific questions. After installation, our software can quickly and efficiently provide valid data as a further working foundation, "commented Dr. Tobias Abthoff, Chairman of NorCom Information Technology AG.


About DaSense
DaSense is an extremely high-performance, open development platform that can be used for big data projects of all kinds. It serves the safety and production standards of large companies.

In addition to the on-premise installation of DaSense, NorCom also offers DaSense "as a service" in the cloud. New customers can simply use the intelligent product without having to make big initial investments. Inventory customers can scale existing installations quickly worldwide.

NorCom offers a DaSense test access via Microsoft Azure as a cloud solution. Test data can be uploaded via secure access and analyzed with DaSense (contact info@dasense.de)


17.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

News im Fokus

Commerzbank baut Privatkundenberatung zu ETFs aus

19. Januar 2018, 14:10

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

19. Januar 2018